Last update 29 Nov 2024
Entacingene turiparvovec (MeiraGTx)
Last update 29 Nov 2024
Overview
Basic Info
Drug Type AAV based gene therapy |
Synonyms Adenovirus Associated Viral Vector Serotype 8 Containing The Human Cngb3 Gene, Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene - MeiraGTx, Entacingene Turiparvovec + [4] |
Target |
Mechanism CNGB3 gene stimulants(Cyclic nucleotide-gated cation channel beta-3 gene stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (EU) |
Login to view timeline
Related
2
Clinical Trials associated with Entacingene turiparvovec (MeiraGTx)Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
100 Clinical Results associated with Entacingene turiparvovec (MeiraGTx)
Login to view more data
100 Translational Medicine associated with Entacingene turiparvovec (MeiraGTx)
Login to view more data
100 Patents (Medical) associated with Entacingene turiparvovec (MeiraGTx)
Login to view more data
100 Deals associated with Entacingene turiparvovec (MeiraGTx)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Color Vision Defects | Phase 2 | US | 03 Jan 2023 | |
| Achromatopsia 1 | Phase 2 | US | 16 Jan 2017 | |
| Achromatopsia 1 | Phase 2 | US | 16 Jan 2017 | |
| Achromatopsia 1 | Phase 2 | GB | 16 Jan 2017 | |
| Achromatopsia 1 | Phase 2 | GB | 16 Jan 2017 | |
| Achromatopsia 3 | Phase 2 | US | 16 Jan 2017 | |
| Achromatopsia 3 | Phase 2 | US | 16 Jan 2017 | |
| Achromatopsia 3 | Phase 2 | GB | 16 Jan 2017 | |
| Achromatopsia 3 | Phase 2 | GB | 16 Jan 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 23 | (Low Dose AAV - CNGB3) | gmujhgypyd(vkuiiezquk) = ofckopnyta jbqmgylila (ongqvjiacd, xxfifudspv - unqnjdkfkk) View more | - | 08 Mar 2023 | ||
(Intermediate Dose AAV-CNGB3) | gmujhgypyd(vkuiiezquk) = freddireai jbqmgylila (ongqvjiacd, bbcniamppl - qdmlismbwf) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free